Compare Google Inc (GOOG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Google Inc is far larger — about 419.4× State Street SPDR S&P Biotech ETF's market cap, and Google Inc pays a 0.26% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GOOG | XBI | |
|---|---|---|
Market Cap | $4.24T | $10.11B |
Volume | 13,937,902 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $399.06 | $169.55 |
52-Week Low | $237.49 | $104.99 |
Typical Hold Time | 137 Days | 38 Days |
Enterprise Value | $4.13T | — |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, down 0.72% today, with a bullish technical signal from moving averages and strong support near $342. The company reported robust Q2 2026 EPS of $9.11, beating expectations, with revenue growth accelerating to $402.84B in 2025. Analyst consensus is strongly bullish with an 87% buy rating and a $435.24 price target, though recent news highlights rising capital expenditures and potential free cash flow pressures.
Outlook remains positive driven by AI and cloud expansion, but risks include heightened spending, regulatory scrutiny, and class-action lawsuits. The stock's valuation at a P/E of 17.3 appears reasonable given high profitability margins, positioning it for long-term growth if execution continues.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
